Nature Communications (Mar 2023)
ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
- Oliver J. Mainwaring,
- Holger Weishaupt,
- Miao Zhao,
- Gabriela Rosén,
- Anna Borgenvik,
- Laura Breinschmid,
- Annemieke D. Verbaan,
- Stacey Richardson,
- Dean Thompson,
- Steven C. Clifford,
- Rebecca M. Hill,
- Karl Annusver,
- Anders Sundström,
- Karl O. Holmberg,
- Maria Kasper,
- Sonja Hutter,
- Fredrik J. Swartling
Affiliations
- Oliver J. Mainwaring
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Holger Weishaupt
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Miao Zhao
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Gabriela Rosén
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Anna Borgenvik
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Laura Breinschmid
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Annemieke D. Verbaan
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Stacey Richardson
- Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer
- Dean Thompson
- Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer
- Steven C. Clifford
- Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer
- Rebecca M. Hill
- Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer
- Karl Annusver
- Department of Cell and Molecular Biology, Karolinska Institutet
- Anders Sundström
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Karl O. Holmberg
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Maria Kasper
- Department of Cell and Molecular Biology, Karolinska Institutet
- Sonja Hutter
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- Fredrik J. Swartling
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University
- DOI
- https://doi.org/10.1038/s41467-023-36847-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 19
Abstract
CDKN2A loss and p53 mutations are rare in MYC-driven Group 3 medulloblastomas (MBs). Here the authors generated a transgenic mouse model of Group 3 MB by MYC overexpression and show that MYC suppresses ARF to drive tumorigenesis.
